CA1039652A - Parainfluenza virus vaccine for the control of canine tracheobronchitis (kennel cough) - Google Patents
Parainfluenza virus vaccine for the control of canine tracheobronchitis (kennel cough)Info
- Publication number
- CA1039652A CA1039652A CA219,440A CA219440A CA1039652A CA 1039652 A CA1039652 A CA 1039652A CA 219440 A CA219440 A CA 219440A CA 1039652 A CA1039652 A CA 1039652A
- Authority
- CA
- Canada
- Prior art keywords
- virus
- vaccine
- cell culture
- gelatin
- canine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 91
- 241000700605 Viruses Species 0.000 title claims abstract description 84
- 241000282465 Canis Species 0.000 title claims abstract description 28
- 206010044314 Tracheobronchitis Diseases 0.000 title claims abstract description 21
- 208000002606 Paramyxoviridae Infections Diseases 0.000 title abstract description 19
- 206010011224 Cough Diseases 0.000 title abstract description 11
- 210000003292 kidney cell Anatomy 0.000 claims abstract description 13
- 238000004113 cell culture Methods 0.000 claims description 24
- 108010010803 Gelatin Proteins 0.000 claims description 19
- 229920000159 gelatin Polymers 0.000 claims description 19
- 239000008273 gelatin Substances 0.000 claims description 19
- 235000019322 gelatine Nutrition 0.000 claims description 19
- 235000011852 gelatine desserts Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000003306 harvesting Methods 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000001902 propagating effect Effects 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 92
- 230000034994 death Effects 0.000 description 18
- 231100000517 death Toxicity 0.000 description 18
- 208000023504 respiratory system disease Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- 230000003442 weekly effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001353878 Canine parainfluenza virus Species 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 208000000655 Distemper Diseases 0.000 description 4
- 208000014058 canine distemper Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000009021 pre-vaccination Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004237 neck muscle Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- KOWWOODYPWDWOJ-LVBPXUMQSA-N elatine Chemical compound C([C@]12CN(C3[C@@]45OCO[C@]44[C@H]6[C@@H](OC)[C@@H]([C@H](C4)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]5OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O KOWWOODYPWDWOJ-LVBPXUMQSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44001574A | 1974-02-06 | 1974-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1039652A true CA1039652A (en) | 1978-10-03 |
Family
ID=23747082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA219,440A Expired CA1039652A (en) | 1974-02-06 | 1975-02-05 | Parainfluenza virus vaccine for the control of canine tracheobronchitis (kennel cough) |
Country Status (10)
-
1975
- 1975-01-30 GB GB4031/75A patent/GB1495026A/en not_active Expired
- 1975-02-04 FR FR7503387A patent/FR2259617B1/fr not_active Expired
- 1975-02-04 AU AU77868/75A patent/AU497239B2/en not_active Expired
- 1975-02-05 SE SE7501244A patent/SE7501244L/ unknown
- 1975-02-05 CA CA219,440A patent/CA1039652A/en not_active Expired
- 1975-02-05 NL NL7501358A patent/NL7501358A/xx not_active Application Discontinuation
- 1975-02-05 NO NO750364A patent/NO750364L/no unknown
- 1975-02-06 DE DE19752505066 patent/DE2505066A1/de not_active Withdrawn
- 1975-02-06 JP JP50015862A patent/JPS50140625A/ja active Pending
- 1975-02-06 IT IT67301/75A patent/IT1030101B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| JPS50140625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-11-11 |
| GB1495026A (en) | 1977-12-14 |
| AU7786875A (en) | 1976-08-05 |
| SE7501244L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-08-07 |
| FR2259617A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-08-29 |
| IT1030101B (it) | 1979-03-30 |
| DE2505066A1 (de) | 1975-08-07 |
| FR2259617B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-08-04 |
| AU497239B2 (en) | 1978-12-07 |
| NL7501358A (nl) | 1975-08-08 |
| NO750364L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0073547B1 (en) | Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines and infectious-bronchitis virus strain | |
| FI85222B (fi) | Hund parvovirusstam och foerfarande foer framstaellning av ett hund parvovirusvaccin. | |
| JPH06503708A (ja) | 不活性化マイコプラズマ・ハイオニューモニエ・バクテリンおよびその使用方法 | |
| Rockborn | Canine distemper virus in tissue culture | |
| US4317811A (en) | Herpes simplex type 1 subunit vaccine | |
| EP0030063B1 (en) | Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strains | |
| US4357320A (en) | Infectious bronchitis vaccine for poultry | |
| Jeggo et al. | Serial inoculation of sheep with two bluetongue virus types | |
| US4571386A (en) | Feline infectious peritonitis vaccine | |
| US3961046A (en) | Mumps vaccine and preparation thereof | |
| US3479430A (en) | Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same | |
| US3585266A (en) | Live rabies virus vaccine and method for the production thereof | |
| CA1039652A (en) | Parainfluenza virus vaccine for the control of canine tracheobronchitis (kennel cough) | |
| US4500638A (en) | Infectious bronchitis virus strain | |
| US2965544A (en) | Tissue culture propagated canine distemper virus and vaccine thereof | |
| US3904750A (en) | Parainfluenza virus vaccine for the control of canine tracheo-bronchitis (kennel cough) | |
| US3562387A (en) | Mink virus enteritis vaccine and method for the production thereof | |
| US3585108A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| US4215107A (en) | Parainfluenza virus vaccine and its preparation | |
| US5232694A (en) | Canine corona virus vaccine | |
| US2915436A (en) | Process for the attenuation of infectious canine hepatitis virus and a vaccine prepared therefrom | |
| US3098011A (en) | Process of producing a vaccine against distemper | |
| US20040170652A1 (en) | Saponin inactivated mycoplasma vaccine | |
| US4515777A (en) | Vaccines | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same |